TY PHAR.(SZ:002728) Xin Lang Cai Jing·2025-08-22 15:03Core Viewpoint - The company has significantly improved its operational performance, with a focus on enhancing its marketing structure and expanding its product sales, particularly the "Te Yi" cough tablets, which have shown a strong recovery in sales volume [1] Group 1: Company Performance - The company completed a comprehensive upgrade of its marketing organizational structure, resulting in a net increase of over 100 frontline sales personnel [1] - The sales volume of the core product "Te Yi" cough tablets reached 331 million pieces, which is 61.29% of the same period in 2023 [1] - For the first half of 2025, the company's operating revenue was 491.43 million yuan, representing a year-on-year growth of 56.54%, while net profit was 38.01 million yuan, a year-on-year increase of 1313.23% [1] Group 2: Product Strategy - The company plans to achieve an annual sales volume of 2.4 billion pieces of cough tablets within 3 to 5 years, targeting a compound annual growth rate of nearly 20% and a pharmacy coverage rate of around 40% [1] - The company is focusing on the online sales growth of cough tablets, which, although currently small, has significant potential for rapid expansion [1] - The company is actively cultivating the skin disease blood toxin pill as a key product, leveraging the distribution channels of cough tablets to promote it [1] Group 3: Marketing and Sales Strategy - The company employs a diversified marketing strategy that includes television, new media, and ground media [1] - In the coming years, the company will focus on cough tablets, with total sales expenses expected to increase while their proportion will gradually decrease [1] - The company maintains a positive attitude towards external growth opportunities, including potential mergers and acquisitions to enhance competitiveness [1]